1. Scrip
  2. >>Business
  3. >>Strategy

BridgeBio Spins Out Cancer Arm With $200m Fundraise

 
• By Joseph Haas

BridgeBio will narrow its focus to rare diseases and the November action date for acoramidis, while subsidiary TheRas will become BridgeBio Oncology Therapeutics, focused on KRAS-targeted drugs.

Spinout
BridgeBio will narrow focus and reduce cash-burn with cancer spinout • Source: Shutterstock

BridgeBio Pharma, Inc. announced a $200m venture financing on 2 May that will enable portfolio oncology firm TheRas to spin out as BridgeBio Oncology Therapeutics (BBOT), a private and independent entity in which the corporate parent will own a less-than-50% equity stake. The move enables BBOT to focus on its KRAS- and PI3K-targeting cancer candidates – one in Phase I and the others in late preclinical development – while BridgeBio saves cash and focuses on the expected approval of Bayer AG-partnered acoramidis in November and other proprietary pipeline assets.

Key Takeaways

  • BridgeBio spins out KRAS-focused cancer firm TheRas into BridgeBio Oncology Therapeutics, while raising a $200m funding round for the new company.

  • BBOT will be...

BBOT’s immediate priority is continuing enrollment in the Phase I ONKORAS-101 study of BBO-5520, a KRAS G12C inhibitor, in KRAS G12C-mutated non-small cell lung cancer (NSCLC). The company thinks the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

More from Business

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.